Causes of Alzheimer's disease.

It is now understood that genetic factors play a crucial role in the risk of developing Alzheimer's disease (AD). Rare mutations in at least 3 genes are responsible for early-onset familial AD. A common polymorphism in the apolipoprotein E gene is the major determinant of risk in families with late-onset AD, as well as in the general population. Advanced age, however, remains the major established risk factor for AD, although environmental variables may also have some role in disease expression. Some pathogenic factors directly associated with aging include oxidative damage and mutations in messenger RNA. Other factors unrelated to the aging process may, in the future, be amenable to therapeutic intervention by way of estrogen replacement therapy for postmenopausal women, anti-inflammatory drug therapy and reducing vascular risk factors. Older theories, such as aluminum playing a role in the pathogenesis of AD, have been mostly discarded as our understanding of pathogenic mechanisms of AD has advanced.

[1]  C. Patterson,et al.  The Recognition, Assessment and Management of Dementing Disorders: Conclusions from the Canadian Consensus Conference on Dementia , 1999, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[2]  M. Swash,et al.  Neurofibrillary neuronal degeneration in dialysis dementia: a feature of aluminum toxicity. , 1987, Clinical neuropathology.

[3]  R. Davis,et al.  Cybrids in Alzheimer's disease: A cellular model of the disease? , 1997, Neurology.

[4]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Munoz,et al.  Qualitative and Quantitative Differences in Senile Plaque Dystrophie Neurites of Alzheimer's Disease and Normal Aged Brain , 1995, Journal of neuropathology and experimental neurology.

[6]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .

[7]  T. Koepsell,et al.  A case‐control study of Alzheimer's disease , 1990, Annals of neurology.

[8]  A. Paterson,et al.  Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. , 1998, JAMA.

[9]  Bradley T. Hyman,et al.  Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease , 1992, Neurology.

[10]  A. Viste,et al.  Mortality from dementia among gastroduodenal ulcer patients. , 1991, Journal of epidemiology and community health.

[11]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[12]  K. Pettigrew,et al.  Discordance and concordance of dementia of the Alzheimer type (DAT) in monozygotic twins indicate heritable and sporadic forms of Alzheimer's disease , 1991, Neurology.

[13]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[14]  V Hachinski,et al.  The effect of different diagnostic criteria on the prevalence of dementia. , 1997, The New England journal of medicine.

[15]  T. Iwatsubo,et al.  Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques. , 1996, The American journal of pathology.

[16]  Joseph S. Beckman,et al.  Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.

[17]  J. Manson,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[18]  D P Forster,et al.  Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: a case-control study in northern England. , 1995, Journal of epidemiology and community health.

[19]  D. Coakley,et al.  Bone aluminium content in Alzheimer's disease. , 1995, Dementia.

[20]  W F Stewart,et al.  Risk of Alzheimer's disease and duration of NSAID use , 1997, Neurology.

[21]  K P Offord,et al.  Lack of association between Alzheimer's disease and education, occupation, marital status, or living arrangement , 1992, Neurology.

[22]  B. Tycko,et al.  Synergistic Effects of Traumatic Head Injury and Apolipoprotein-epsilon4 in Patients With Alzheimer's Disease , 1995, Neurology.

[23]  D. Butterfield,et al.  Direct evidence of oxidative injury produced by the Alzheimer's β-Amyloid peptide (1–40) in cultured hippocampal neurons , 1995, Experimental Neurology.

[24]  J. Price,et al.  Cerebral amyloid deposition and diffuse plaques in ``normal'' aging , 1996, Neurology.

[25]  L. Fratiglioni,et al.  Risk factors for clinically diagnosed Alzheimer's disease , 1986, Neurology.

[26]  G A Colditz,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[27]  E B Larson,et al.  Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. , 1994, American journal of epidemiology.

[28]  G. Belle,et al.  The association between aluminum-containing products and Alzheimer's disease. , 1990, Journal of clinical epidemiology.

[29]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[30]  Rachelle S. Doody,et al.  DONEPEZIL STUDY GROUP. A 24-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF DONEPEZIL IN PATIENTS WITH ALZHEIMER'S DIS-EASE , 1998 .

[31]  C Osmond,et al.  GEOGRAPHICAL RELATION BETWEEN ALZHEIMER'S DISEASE AND ALUMINIUM IN DRINKING WATER , 1989, The Lancet.

[32]  R B D'Agostino,et al.  The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study , 1995, Neurology.

[33]  K. Gautschi,et al.  Failure to find a relationship between mnestic skills of octogenarians and aluminum in drinking water , 1991, International archives of occupational and environmental health.

[34]  K. Davis,et al.  The search for disease-modifying treatment for Alzheimer's disease , 1997, Neurology.

[35]  A. Kaszniak,et al.  Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.

[36]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[37]  Anthony F Jorm,et al.  A case‐control study of Alzheimer's disease in Australia , 1990, Neurology.

[38]  S. Birge The role of estrogen in the treatment of Alzheimer's disease , 1997, Neurology.

[39]  E. Salib,et al.  A Case-Control Study of Alzheimer's Disease and Aluminium Occupation , 1996, British Journal of Psychiatry.

[40]  D. Coggon,et al.  Aluminum Concentrations in Drinking Water and Risk of Alzheimer's Disease , 1997, Epidemiology.

[41]  M. Mesulam,et al.  Butyrylcholinesterase in the life cycle of amyloid plaques , 1997, Annals of neurology.

[42]  R. Wyatt,et al.  Aluminum and Alzheimer's Disease , 1983, The Journal of nervous and mental disease.

[43]  R. Brookmeyer,et al.  A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease , 1997, Neurology.

[44]  Claudia H. Kawas,et al.  The epidemiology of dementia and Alzheimer disease. , 1994 .

[45]  K. Beyreuther,et al.  Genes contributing to Alzheimer's disease. , 1996, Molecular psychiatry.

[46]  R. Horwitz,et al.  The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. , 1997, Journal of clinical epidemiology.

[47]  A D Roses,et al.  Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.

[48]  N Howell,et al.  Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Truls Østbye,et al.  Net economic costs of dementia in Canada. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[50]  M. Norenberg,et al.  A FATAL ENCEPHALOPATHY IN CHRONIC HÆMODIALYSIS PATIENTS , 1976, The Lancet.

[51]  A. Alzheimer Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .

[52]  M. Roth,et al.  The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.

[53]  S. Gauthier,et al.  Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[54]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[55]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[56]  C. Masters,et al.  Alzheimer's disease: The ins and outs of amyloid-β , 1997, Nature.

[57]  F. Grosveld,et al.  Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. , 1998, Science.

[58]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. , 1996, Dementia.

[59]  K. Marder,et al.  Alzheimer's disease after remote head injury: an incidence study. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[60]  E. Bjertness,et al.  Content of Brain Aluminum Is Not Elevated in Alzheimer Disease , 1996, Alzheimer disease and associated disorders.

[61]  G. Chazot,et al.  The Physiology and Pharmacology of Melatonin in Humans , 1998, Hormone Research in Paediatrics.

[62]  D. Munoz,et al.  Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging , 1998, Neurology.

[63]  A. Roses Apolipoprotein E Affects the Rate of Alzheimer Disease Expression: (β-Amyloid Burden Is a Secondary Consequence Dependent on APOE Genotype and Duration of Disease , 1994, Journal of neuropathology and experimental neurology.

[64]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[65]  D R Wekstein,et al.  Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. , 1996, JAMA.

[66]  Mark A. Smith,et al.  4‐Hydroxynonenal‐Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease , 1997, Journal of neurochemistry.

[67]  W E Wilkinson,et al.  Alzheimer's disease: A study of epidemiological aspects , 1984, Annals of neurology.

[68]  D. Selkoe,et al.  Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments , 1992, Nature.

[69]  B. Mcdonald,et al.  Absence of aluminium in neuritic plaque cores in Alzheimer's disease , 1992, Nature.

[70]  W. D. Ehmann,et al.  Laser microprobe analysis of brain aluminum in Alzheimer' disease , 1993, Annals of neurology.

[71]  Arto Mannermaa,et al.  A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ε4 allele , 1995, Neuroscience Letters.

[72]  P. Matsudaira,et al.  Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[73]  R. Mayeux,et al.  Influence of education and occupation on the incidence of Alzheimer's disease. , 1994, JAMA.

[74]  H. Feldman,et al.  Serum levels of the iron binding protein p97 are elevated in Alzheimer′s disease , 1996, Nature Medicine.

[75]  Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. American Psychiatric Association. , 1997, American Journal of Psychiatry.

[76]  M. Pericak-Vance,et al.  Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs , 1995, Neurobiology of Aging.

[77]  D. Rubinsztein The genetics of Alzheimer's disease , 1997, Progress in Neurobiology.

[78]  S. Shapiro,et al.  Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. , 1985, The New England journal of medicine.

[79]  J. Haines,et al.  Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. , 1997, JAMA.

[80]  Canadian study of health and aging: study methods and prevalence of dementia. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[81]  Neuropathological stageing of Alzheimer related changes correlates with psychometrically assessed intellectual status H. Braak, C. Duyckaerts, E. Braak and F. Piette. Depts of Anatomy and Neuropathology, Goethe University and Hopital de la Salpetriere, Frankfurt, Germany and Paris, France , 1992, Neurobiology of Aging.

[82]  M. Mattson,et al.  A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[83]  D. Salmon,et al.  The prevalence of dementia and Alzheimer's disease in Shanghai, China: Impact of age, gender, and education , 1990, Annals of neurology.

[84]  P. Mcgeer,et al.  The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.

[85]  S. Gauthier,et al.  Alzheimer's disease: current knowledge, management and research. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[86]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[87]  N. Relkin,et al.  Apolipoprotein E genotyping in Alzheimer's disease , 1996, The Lancet.

[88]  V. Henderson The epidemiology of estrogen replacement therapy and Alzheimer's disease , 1997, Neurology.

[89]  KennethRockwood,et al.  The Canadian Study of Health and Aging* , 1994, Neurology.